WR

Warby Parker Inc.

WRBYHealthcareNASDAQ

Medical Instruments & Supplies

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$871.9M
+13.0% YoY
Net Income
$1.6M
+108.0% YoY
EBITDA
$44.9M
+185.3% YoY
Free Cash Flow
$9.5M

Scan Results

Daily timeframe
DateIndicatorDetails
Sep 1 Below MA2000.4% below MA200
Aug 31CONFIRMED Below MA1500.5% below MA150
MACD Negative CrossoverHistogram -0.1579, negative momentum
About Warby Parker Inc.

Warby Parker Inc. sells eyewear products through its retail and e-commerce platform in the United States and Canada. Valued at $3.01B, WRBY is a mid-cap name in its sector. The company offers eyeglasses and sunglasses; and single-vision, progressive, light-responsive, polarized, blue-light-filtering, tinted, non-prescription, and contact lenses.

Where WRBY stands vs its 150-day and 200-day moving averages

As of the September 1, 2026 close, WRBY finished 1.99% below its 150-day moving average ($25.10) and 0.40% below its 200-day moving average ($24.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is WRBY overbought or oversold?

At the September 1, 2026 close, WRBY's RSI(14) was 47.2, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$3.01B
P/E (TTM)405.83
Fwd P/E39.61
EPS$0.06
Beta1.91
52W Change-9.0%
ROE2.1%
Analysis

The balance sheet looks solid with $292.7M in cash comfortably exceeding the $251.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $9.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 2.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $598.1M (2022) to $871.9M (2025), reflecting a 46% increase over the period.

Warby Parker Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. At over 50x earnings, WRBY carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Warby Parker Inc. and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms